The Eli Lilly's antibody-drug reduces COVID-19 in nursing homes in the latest study

Eli Lilly’s antibody-drug was found to significantly reduce the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, the company said Thursday.

The drug is being evaluated as part of a Phase 3 trial involving 965 participants that were conducted in part by the National Institute of Allergy and Infectious Diseases and the COVID-19 Prevention Network...

See the whole story on Fox Business right here,


© 2021 by Covid Plasma Initiative Foundation

The Yitzchok Lebovits COVID Plasma Initiative is dedicated in memory of R’ Yitzchok a"h Ben R’ Moshe Eliezer y"blt, who recently passed away. R' Yitzchok was a brother of Chaim Lebovits who has been a driving force behind every aspect of this initiative to bring this life-saving therapy to the people who need it.